journal1 ›› 2017, Vol. 25 ›› Issue (6): 582-584.DOI: 10.11852/zgetbjzz2017-25-06-12

• Orignal Article • Previous Articles     Next Articles

Prevention and treatment of glucocorticoid-induced osteoporosis in children

KANG Xiao-jun, TIAN Zhi-liang   

  1. Department of Pediatrics,the 2nd Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang 150000,China
  • Received:2016-07-04 Online:2017-06-10 Published:2017-06-10
  • Contact: TIAN Zhi-liang,E-mail:tianzhiliang999@aliyun.com

儿童糖皮质激素性骨质疏松的防治

康小俊综述, 田执梁审校   

  1. 哈尔滨医科大学附属第二医院儿科,黑龙江 哈尔滨 150000
  • 通讯作者: 田执梁,E-mail:tianzhiliang999@aliyun.com
  • 作者简介:康小俊(1990-),女,湖南人,土家族,在读硕士,主要研究方向为儿童哮喘。

Abstract: Glucocorticoids (GCs) is widely used in pediatric practice.Long-term systemic GC therapy is associated with many side-effects,including low bone mineral density (BMD) and fractures.In adults,evidence-based guidelines exist to base management of patients with glucocorticoid-induced osteoporosis.Children of glucocorticoid glucocorticoid-induced osteoporosis is becoming more and more brought to the attention of the pediatrician,but information about children is still very few.This article mainly summarized the prevention and treatment of glucocorticoid-induced osteoporosis in children.

Key words: osteoporosis, glucocorticoid, bone mineral density, diphosphonate

摘要: 糖皮质激素在儿科疾病中应用广泛,长期应用糖皮质激素可导致骨密度减低及骨折等。在成人,存在管理糖皮质激素性骨质疏松症的循证指南,儿童糖皮质激素性骨质疏松症也越来越受到儿科医师的重视,但有关儿童的信息还是非常少,本文主要对儿童糖皮质激素性骨质疏松的预防和治疗进行综述。

关键词: 骨质疏松, 糖皮质激素, 骨密度, 膦酸盐

CLC Number: